Dr. Bruce E. Brockstein
Claim this profileNorthShore University HealthSystem-Evanston Hospital
Studies Glioblastoma
Studies Skin Cancer
11 reported clinical trials
21 drugs studied
Area of expertise
1Glioblastoma
TMB
EGFR
+7/-10
2Skin Cancer
BRAF positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Bruce E. Brockstein is currently running
Cemiplimab + Palbociclib
for Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Recruiting1 award Phase 2
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
More about Bruce E. Brockstein
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Bruce E. Brockstein has experience with
- Nivolumab
- Ipilimumab
- Radiation Therapy
- Cisplatin
- Intensity-Modulated Radiation Therapy
- AL102
Breakdown of trials Bruce E. Brockstein has run
Skin Cancer
Cutaneous Melanoma
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bruce E. Brockstein specialize in?
Bruce E. Brockstein focuses on Glioblastoma and Skin Cancer. In particular, much of their work with Glioblastoma has involved TMB patients, or patients who are EGFR.
Is Bruce E. Brockstein currently recruiting for clinical trials?
Yes, Bruce E. Brockstein is currently recruiting for 4 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that Bruce E. Brockstein has studied deeply?
Yes, Bruce E. Brockstein has studied treatments such as Nivolumab, Ipilimumab, Radiation Therapy.
What is the best way to schedule an appointment with Bruce E. Brockstein?
Apply for one of the trials that Bruce E. Brockstein is conducting.
What is the office address of Bruce E. Brockstein?
The office of Bruce E. Brockstein is located at: NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the NorthShore University HealthSystem-Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.